United States Patent 9,345,695 Scope and Claims Analysis: Esomeprazole Not-Enteric-Coated With pH-Triggered Enteric Naproxen in Unit Dosage Form
Executive summary: U.S. Patent 9,345,695 claims a combination unit dosage that co-administers esomeprazole (at least partially not enteric-coated) and naproxen in an enteric-release coating system that only dissolves in pH ≥ 3.5. The claimed technology is defined by (1) the coating state of esomeprazole, (2) the release-trigger threshold and coating chemistry for naproxen, and (3) a release behavior requirement where at least some esomeprazole is released regardless of medium pH. The claims are structured to distinguish over conventional “both-drugs enteric-coated” or “all drugs pH-dependent” systems, and they target a specific dose-range combination in dependent claims.
What is US Patent 9,345,695 claim scope for esomeprazole and naproxen combination tablets?
Core claim 1 scope (independent claim): The patent claims a pharmaceutical composition in unit dosage form comprising:
- Esomeprazole: a “therapeutically effective amount” where at least a portion is not surrounded by an enteric coating.
- Naproxen: a therapeutically effective amount, where naproxen is surrounded by a coating that inhibits release from the unit dosage form unless the unit is in a medium with pH ≥ 3.5.
- Coating composition requirement: the naproxen coating comprises methacrylic acid copolymers.
- Release-behavior requirement: the unit dosage form releases esomeprazole such that upon introduction into a medium, at least a portion of esomeprazole is released regardless of the pH of that medium.
Claim construction implications for freedom-to-operate
- Esomeprazole not enteric-coated “at least a portion” means the claim covers mixed populations in the same dosage form, such as:
- partially enteric-coated esomeprazole particles mixed with non-enteric-coated particles, or
- esomeprazole not otherwise encapsulated with enteric material, or
- esomeprazole granules where some fraction lacks enteric coverage.
- Naproxen enteric coating “inhibits release unless pH ≥ 3.5” imposes a functional threshold tied to dissolution conditions. This is not a mere “enteric-coated” label; it is a performance criterion anchored to pH.
- Methacrylic acid copolymer narrows naproxen coating chemistry. If a design uses other enteric polymers (e.g., cellulose acetate phthalate, HPMCAS, Eudragit L/S alternative grades not described as methacrylic acid copolymers), it can fall outside the explicit material requirement.
- “At least a portion of esomeprazole released regardless of pH” creates an additional performance limiter. A generic design that makes esomeprazole pH-dependent (for example, fully enteric-coated esomeprazole) is structurally and functionally distinct.
Practical “design-around” pressure points
The claim is built from three “must-have” pillars: (i) partial absence of enteric coating on esomeprazole, (ii) pH-triggered inhibition for naproxen at pH ≥ 3.5 using methacrylic acid copolymers, and (iii) pH-independent esomeprazole release behavior.
Any design that fails one pillar can avoid literal claim coverage. The most likely commercial design-around pathways are:
- switching the naproxen coating polymer family away from methacrylic acid copolymers, or
- moving the naproxen dissolution trigger away from pH ≥ 3.5 behavior (either higher or not clearly pH-dependent as claimed), or
- making esomeprazole fully enteric-coated so that release becomes pH-dependent.
How does claim 1 define the pH threshold and coating chemistry for naproxen release?
Naproxen release inhibition trigger: The claim requires a coating that “inhibits its release … unless … in a medium with a pH of 3.5 or higher.”
This reads as a gelatinous/enteric dissolution threshold around pH 3.5. The claim does not require a particular lag time, dissolution rate profile, or specific test method in the excerpt, but it anchors the behavior to a defined pH.
Methacrylic acid copolymers: The naproxen coating is required to comprise methacrylic acid copolymers. In many enteric systems, methacrylic acid copolymers correspond to well-known Eudragit-type materials, but the legal relevance is that claim 1 expressly requires the coating “comprises methacrylic acid copolymers,” which is typically interpreted as a material presence requirement.
Claim scope impact
- If naproxen is coated with a polymer that does not meet the methacrylic acid copolymer definition, the claim likely does not read on that formulation.
- If the coating is a blend that includes methacrylic acid copolymers plus other excipients, it can still meet “comprises,” which is a typical open-ended transitional phrase in US claim drafting.
What does “esomeprazole not surrounded by enteric coating” mean for infringement risk?
Claim 1 requires: “esomeprazole, wherein at least a portion of said esomeprazole is not surrounded by an enteric coating.”
Coverage modes
- Partially enteric-coated esomeprazole: some fraction lacks enteric coverage while another fraction might be enteric-coated.
- No enteric coating for esomeprazole granules/particles: the “at least a portion” condition is met.
- Formulation architecture can be explicit (separate layers or particles) or implicit (manufacturing produces non-enteric-coated portion).
Release-behavior tie-in
The claim also requires that the unit dosage form provides esomeprazole release regardless of medium pH. That requirement tightens scope: even if a portion is not enteric-coated, the dosage form could be designed so that release at low pH is still suppressed by other mechanisms (for example, physical barriers). Such a design could create non-infringement if it fails the release behavior requirement.
How strong are dependent claims 2–4 on dose ranges for naproxen and esomeprazole?
Claim 2: Naproxen is present in the unit dosage form in an amount of 200–600 mg.
Claim 3: Esomeprazole is present in the unit dosage form in an amount of 5–100 mg.
Claim 4: Naproxen in 200–600 mg and esomeprazole in 5–100 mg with a per-unit relationship.
Legal and commercial impact
- Dependent claims narrow the independent claim to specific therapeutic dosing bands.
- If a competitor’s unit dose uses naproxen outside 200–600 mg (for example, 100 mg) or esomeprazole outside 5–100 mg, it can avoid dependent-claim coverage, while still potentially implicating claim 1 if therapeutically effective amounts are used and the core coating/release elements are met.
- If a competitor stays within these dosing bands, the dependent claims become direct infringement targets if the coating/release pillars also match.
What formulation elements are required in a unit dosage form to fall within US 9,345,695?
A product must satisfy all claim 1 elements simultaneously:
- Unit dosage form (single dosage containing both active components).
- Therapeutically effective esomeprazole with at least a portion not enteric-coated.
- Therapeutically effective naproxen with enteric coating that:
- inhibits release unless pH ≥ 3.5, and
- the coating includes methacrylic acid copolymers.
- Esomeprazole release irrespective of pH upon introduction into a medium.
- Dependent limitation if dose ranges are targeted (claims 2–4).
“All elements at once” risk profile
In litigation and licensing, this structure creates a higher bar for a generic applicant: it must replicate both:
- a partial non-enteric esomeprazole strategy, and
- a specific enteric naproxen coating behavior (polymer class plus pH threshold), and
- a pH-independent esomeprazole release performance.
What patent landscape factors are implicated by this claim set (combination PPI + NSAID with differential coating)?
Even without external bibliographic identifiers, the claim structure indicates the patent is aimed at a formulation class where:
- PPIs (omeprazole/esomeprazole class) are sometimes enteric-coated in standard practice to protect from acid degradation, while
- NSAIDs like naproxen often require enteric protection to reduce GI irritation,
- this patent’s differentiator is breaking the symmetry: naproxen is protected via a pH-triggered enteric coating, while esomeprazole has at least some fraction not enteric-coated to enable pH-independent release.
That differentiation typically creates freedom-to-operate leverage versus patents claiming:
- both actives fully enteric-coated to align release timing, or
- tablet designs where both actives exhibit pH-dependent release.
Landscape search guidance tied to these claim pillars
A thorough landscape typically clusters nearby patents by:
- enteric polymer class (methacrylic acid copolymers versus other enteric polymers),
- pH threshold language (3.0, 3.5, 4.0, 5.0),
- split-particle or partial coating strategies,
- “regardless of pH” release performance for PPIs.
This patent’s explicit language suggests it belongs to a sub-family of differential-coating combination formulations.
What would a non-infringing generic scenario look like under claim 1?
A generic could reduce or eliminate literal claim 1 exposure by breaking at least one required element:
-
Naproxen coating not comprising methacrylic acid copolymers
- Use alternative enteric polymers outside claim requirement.
-
Naproxen coating trigger not tied to pH ≥ 3.5 inhibition
- If dissolution/retardation behavior does not match the claimed trigger.
-
Esomeprazole fully enteric-coated
- If at least some fraction is still not enteric-coated, literal risk remains; full coverage is the cleanest path.
-
Prevent esomeprazole release “regardless of pH”
- Even if some fraction is not enteric-coated, a dosage form can be engineered to prevent release at low pH via physical barrier or other coatings that still inhibit esomeprazole release. This would be a non-infringement argument anchored to the performance clause.
-
Dose-range design around dependent claims (2–4)
- Changing dose outside 200–600 mg naproxen or 5–100 mg esomeprazole may defeat dependent coverage, while independent coverage still depends on the core coating/release elements.
Key takeaways
- Independent claim 1 is centered on a differential coating scheme: esomeprazole has at least part not enteric-coated and must release regardless of pH, while naproxen is enteric-coated with methacrylic acid copolymers and must inhibit release until pH ≥ 3.5.
- The claim is strong against symmetrical enteric-coating designs and against formulations that do not meet the explicit methacrylic acid copolymer and pH ≥ 3.5 performance thresholds.
- Dependent claims 2–4 narrow infringement to dose bands: naproxen 200–600 mg, esomeprazole 5–100 mg, and the corresponding combined per-unit range.
FAQs
1) Does US 9,345,695 cover tablets where esomeprazole is only partially coated with enteric polymer?
Yes. Claim 1 requires only that “at least a portion” of esomeprazole is not surrounded by an enteric coating, coupled with the pH-independent release requirement.
2) If naproxen uses an enteric polymer other than methacrylic acid copolymers, does it avoid claim 1?
It can, because claim 1 expressly requires the naproxen coating comprises methacrylic acid copolymers.
3) Is “pH 3.5 or higher” a hard cutoff in the claim language?
The claim ties release inhibition to medium pH being 3.5 or higher for release, so designs where the effective trigger is outside that behavior present a non-infringement path.
4) Can a product infringe claim 1 even if its doses fall outside 200–600 mg naproxen or 5–100 mg esomeprazole?
Yes. Claims 2–4 are dose-limiting dependents; claim 1 covers “therapeutically effective amounts” and is not restricted to those specific ranges.
5) What is the single most important performance requirement for esomeprazole in claim 1?
That the unit dosage form provides for esomeprazole release such that at least a portion is released regardless of the pH of the medium.
References (APA)
- United States Patent No. 9,345,695. (Claim text as provided).
